Familial Hypercholesterolaemia
FH and PCSK9: Perspective from Japan
Evolocumab recently received approval in Japan for the treatment of patients with familial hypercholesterolemia (FH, inherited high cholesterol) or hypercholesterolaemia who are at high risk of cardiovascular events and do not adequately respond to statins. Here, Professor Harada-Shiba, Osaka, Japan discusses the importance of this…
read more »
Making Familial Hypercholesterolaemia visible
Image courtesy of the FH Foundation www.thefhfoundation.org
read more »
AHA Agenda on FH: Addressing the burden of underdiagnosed and undertreated FH
Underdiagnosed and undertreated familial hypercholesterolaemia (FH, inherited high cholesterol), is an important contributor to overall coronary heart disease (CHD) death and disability. This issue is clearly highlighted by a study presented at the American Heart Association Scientific Sessions 2015 (1). The investigators used a Markov…
read more »
Familial hypercholesterolaemia (FH)
Why is cholesterol important? Cholesterol, with other fats such as triglycerides, plays a vital role in the structure and function of cells. However, too much cholesterol in the blood (hypercholesterolaemia) is a risk factor for early heart disease, heart attack and stroke. Cholesterol is transported…
read more »
Start treatment early: Maximise benefit
FH is the most common inherited disease in the world – affecting about 30 million people worldwide – of whom only about 1% have been diagnosed. Therefore, it is critically important there is a global effort to start treatment early to prevent children ever developing…
read more »
Genotypic and phenotypic variation in FH – relevance to cardiovascular risk
Professor Frederick Raal FRCP, FRCPC, FCP(SA), MMED, PhD Director, Carbohydrate & Lipid Metabolism Research Unit
read more »
Statin Intolerance: What is it? What are therapeutic options?
Professor Erik Stroes MD PhD Chairman, department of Vascular Medicine
read more »
Making premature CHD history
Dr Samuel Gidding discusses how treating children with FH early can make premature CHD history
read more »
How to identify children with FH
Dr Samuel Gidding discusses how to identify children with FH
read more »
FH in Africa and the Middle East – the great unknown
Why we need a global initiative on FH: FH Connect: Prof Derick Raal, University of the Witwatersrand, Johannesburg, South Africa Expert consensus has already highlighted the extent of underdiagnosis and undertreatment of familial hypercholesterolaemia (FH, inherited high cholesterol), which if untreated increases the lifetime risk…
read more »
FH in Argentina: Why the European Atherosclerosis Society FH Studies Collaboration (EAS-FHSC) is key
PCSK9 Forum caught up with Dr Pablo Corral, ICM Institute Medical Clinic, Buenos Aires, Argentina during the 83rd European Atherosclerosis Society (EAS) Congress in Glasgow, Scotland. The status of FH management in Argentina has improved over the last 2 years. There has been a new…
read more »
FH – the challenges for the next 10 years?
Kees Hovingh, Academic Medical Center, Amsterdam, the Netherlands In a session on familial hypercholesterolaemia (FH, inherited high cholesterol) at the 83rd Annual Congress of the European Atherosclerosis Society (EAS), Dr Kees Hovingh outlined what he saw as the challenges for FH in the next decade….
read more »
The Rationale and Design of the CASCADE FH Registry: Expert Analysis
Familial hypercholesterolemia (FH) is a genetic disease of elevated low-density lipoprotein cholesterol (LDL-C) that affects over one million people in the U.S.1 Left untreated, FH results in a 20-fold increase in the lifetime risk of premature coronary heart disease due to high LDL-C exposure from…
read more »
Cascade Screening for FH: Lessons from Brazil
How can we improve on the detection and treatment of FH? PCSK9 Forum Editor Professor Frederick Raal discusses insights from a recent study in Brazil. Familial hypercholesterolemia (FH) is the most common dominantly inherited condition in humans, affecting 1:200 to 1:500 people or over 30…
read more »
Familial hypercholesterolaemia (FH)
Why is cholesterol important? Cholesterol, with other fats such as triglycerides, plays a vital role in the structure and function of cells. However, too much cholesterol in the blood (hypercholesterolaemia) is a risk factor for early heart disease, heart attack and stroke. Cholesterol is transported…
read more »
Paediatric FH: do you need a genetic diagnosis?
Familial hypercholesterolaemia (FH) is characterised clinically by life-long elevated levels of low-density-lipoprotein cholesterol (LDL-C) and increased risk of premature cardiovascular disease. FH is predominantly due to mutations in the gene encoding the LDL receptor, and less commonly to mutations in the APOB or PCSK9 genes….
read more »
Professor Gerald Watts discusses the 10 countries project in FH
The International Atherosclerosis Society has begun a study in Asia and the Pacific Rim to provide the first comprehensive investigation of the worlds commonest genetic disorder, familial hypercholesterolaemia (FH) in the region. FH results in very high levels of low density lipoprotein cholesterol (LDL-C) and…
read more »
Rising to the Challenge: Implementing Models of Care in FH
Winthrop Professor Gerald F. Watts DSc PhD MD FRACP FRCP, Lipid Disorders Clinic, Cardiovascular Medicine, Royal Perth Hospital School of Medicine and Pharmacology, University of Western Australia. GPO Box X2213, Perth, WA 6847, Australia; E-mail: [email protected] While several guidelines, mostly based on expert opinion, have…
read more »
FH in the statin era: we need to do better
Despite the availability of generic statin therapy, cardiovascular disease accounts for 50% of all deaths in FH patients. Clinicians need to do better, argues Eric Bruckert, Institut E3M et IHU cardiométabolique (ICAN), Hôpital Pitié Salpêtrière, Paris, France. Familial hypercholesterolemia (FH) is a severe condition, which…
read more »
Improving the management of the FH patient
Professor Raul Santos from Brazil says that the new therapies which inhibit PCSK9 to significantly reduce low density Lipoprotein Cholesterol (LDL-C) when given in addition to other cholesterol lowering drugs offer a very important advance in reducing cardiovascular risk in people with Familial Hypercholesterolemia (FH).
read more »
